| "Actinomyces gonidiaformis" (Tunnicliff and Jackson 1925) Bergey et al. 1930| "Bacillus gonidiaformans" Tunnicliff and Jackson 1925| "Pseudobacterium gonidiaformans" (Tunnicliff and Jackson 1925) Krasil'nikov 1949| "Sphaerophorus gonidiaformans" (Tunnicliff and Jackson 1925) Prevot 1938| Actinomyces gonidiaformis| ATCC 25563| Bacillus gonidiaformans| CCUG 16790| DSM 19810| Fusibacterium gonidiaformans| Fusibacterium gonidiiformans| Fusobacterium gonidiaformans| Fusobacterium gonidiaformans (Tunnicliff and Jackson 1925) Moore and Holdeman 1970| Fusobacterium gonidiiformans| Pseudobacterium gonidiaformans| Sphaerophorus gonidiaformans
Periodontal disease: Fusobacterium species, including Fusobacterium gonidiaformans, have been implicated in the development of periodontal disease. These bacteria can contribute to the formation of dental plaque and gingivitis, leading to inflammation of the gums and potential progression to more severe periodontal conditions if left untreated.
Oral infections: Fusobacterium gonidiaformans, along with other Fusobacterium species, can cause various oral infections, including dental abscesses, periodontal abscesses, and infections following dental procedures or oral surgery.
Lemierre's syndrome: Fusobacterium gonidiaformans has been associated with Lemierre's syndrome, a rare but serious condition characterized by a throat infection (often caused by another bacterium, such as Streptococcus) leading to the formation of a septic thrombophlebitis in the internal jugular vein. This can result in septicemia and the formation of abscesses in distant organs, such as the lungs.
Systemic infections: In immunocompromised individuals or those with underlying health conditions, Fusobacterium gonidiaformans can cause systemic infections, including bloodstream infections (bacteremia) and infections of distant sites such as the liver, brain, or joints.
Associated with certain cancers: Some studies have suggested an association between Fusobacterium species, including Fusobacterium gonidiaformans, and certain types of cancer, particularly colorectal cancer. However, the exact role of Fusobacterium in cancer development and progression is still under investigation.
A lot more information is available when you are logged in and raise the display level
Other Sources for more information:
Statistics | NCBI | Data Punk | End Products Produced |
Different labs use different software to read the sample. See this post for more details.
One lab may say you have none, another may say you have a lot! - This may be solely due to the software they are using to estimate.
We deem lab specific values using values from the KM method for each specific lab to be the most reliable.
Lab | Frequency | UD-Low | UD-High | KM Low | KM High | Lab Low | Lab High | Mean | Median | Standard Deviation | Box Plot Low | Box Plot High | KM Percentile Low | KM Percentile High |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Other Labs | 0.75 | 8 | 140 | 0 | 107 | 38.8 | 30 | 34.9 | 8 | 140 | 0 %ile | 100 %ile | ||
biomesight | 19.95 | 0 | 10 | 10 | 25940 | 0 | 22902 | 2105.7 | 30 | 10610.5 | 10 | 270 | 0 %ile | 98.3 %ile |
thorne | 44.83 | 1 | 301 | 0 | 188 | 26.7 | 3 | 82.5 | 1 | 301 | 6.7 %ile | 86.7 %ile | ||
thryve | 0.72 | 13 | 110 | 0 | 105 | 39 | 24 | 33.8 | 13 | 110 | 10 %ile | 80 %ile | ||
ubiome | 0.13 | 0 | 24 | 24 | 24 | 24 | 24 | 0 %ile | 99 %ile |
Source of Ranges | Low Boundary | High Boundary | Low Boundary %age | High Boundary %age |
---|---|---|---|---|
Thorne (20/80%ile) | 0 | 1.84 | 0 | 0.0002 |
XenoGene | 0 | 100 | 0 | 0.01 |
Lab | Frequency Seen | Average | Standard Deviation | Sample Count | Lab Samples |
---|---|---|---|---|---|
BiomeSight | 21.823 % | 0.253 % | 1.357 % | 625.0 | 2864 |
CerbaLab | 66.667 % | 0.001 % | 0 % | 2.0 | 3 |
custom | 13.559 % | 0.003 % | 0 % | 8.0 | 59 |
es-xenogene | 62.069 % | 0.005 % | 0.004 % | 18.0 | 29 |
Medivere | 14.286 % | 0.001 % | % | 1.0 | 7 |
Thorne | 36.667 % | 0.002 % | 0.007 % | 33.0 | 90 |
Thryve | 0.651 % | 0.004 % | 0.003 % | 9.0 | 1383 |
uBiome | 0.126 % | 0.002 % | % | 1.0 | 792 |
Click on Impact for information if high or low levels are causing the impact
Magnitude | Impact | Symptom |
---|
|
And display level must be raised above public.
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.